CSF3 and neutropenia: The combination of docetaxel and epirubicin without G-CSF support resulted in febrile neutropenia in approximately 15% of cycles in a trial by Pagani et al (1999) and in 4 and 7% of cycles in the trials by Morales et al (2004) and Mavroudis et al (2000), respectively.